Unicycive Therapeutics (UNCY) Projected to Post Earnings on Wednesday

Unicycive Therapeutics (NASDAQ:UNCY) is expected to be posting its results before the market opens on Wednesday, May 13th. Analysts expect Unicycive Therapeutics to post earnings of ($0.4589) per share and revenue of $11.1110 million for the quarter.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.36). On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Unicycive Therapeutics Trading Up 1.3%

Shares of NASDAQ UNCY opened at $8.08 on Wednesday. The stock has a market cap of $215.74 million, a price-to-earnings ratio of -3.72 and a beta of 1.78. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.00. The company’s 50-day moving average price is $6.91 and its 200 day moving average price is $6.22.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. B. Riley Financial assumed coverage on shares of Unicycive Therapeutics in a research note on Friday, May 1st. They issued a “buy” rating and a $22.00 price objective on the stock. Benchmark lowered their price objective on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a “speculative buy” rating on the stock in a research note on Monday, April 6th. Guggenheim lowered their price objective on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Wall Street Zen cut shares of Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, March 27th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Unicycive Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $24.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vivo Capital LLC lifted its holdings in Unicycive Therapeutics by 57.4% in the 3rd quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock valued at $7,804,000 after purchasing an additional 652,901 shares in the last quarter. Millennium Management LLC purchased a new position in Unicycive Therapeutics in the 4th quarter valued at about $5,856,000. Vanguard Group Inc. lifted its holdings in Unicycive Therapeutics by 8.7% in the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after purchasing an additional 52,925 shares in the last quarter. Cantor Fitzgerald L. P. purchased a new position in Unicycive Therapeutics in the 4th quarter valued at about $1,154,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Unicycive Therapeutics by 36.2% during the 4th quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock worth $989,000 after acquiring an additional 45,563 shares during the period. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.